Status | Study |
Completed |
Study Name: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Condition: Recurrent Adenoid Cystic Carcinoma of the Salivary Glands Metas Date: 2012-08-23 Interventions: Drug: Dovitinib Treatment continued until Disease Progression, Toxicity, or patient withdrawal |
Active, not recruiting |
Study Name: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma Condition: Recurrent Oral Cavity Adenoid Cystic Carcinoma Recurrent Saliva Date: 2012-05-22 Interventions: Drug: Akt Inhibitor MK2206 Giv |
Completed |
Study Name: Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2012-03-16 Interventions: Drug: AG-013736 (AXITINIB) All eligible patients will receive a starting axitinib dose of 5 mg twice dai |
Completed |
Study Name: Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2012-01-17 Interventions: Drug: Dovitinib (TKI258) 500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) |
Completed |
Study Name: Dovitinib in Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2011-08-09 Interventions: Drug: TKI258 (Dovitinib): TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off sched |
Recruiting |
Study Name: Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Condition: Adenoid Cystic Carcinoma Date: 2010-08-30 Interventions: Drug: Cetuximab cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface |
Active, not recruiting |
Study Name: Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Condition: Recurrent Oral Cavity Adenoid Cystic Carcinoma Recurrent Saliva Date: 2010-08-04 Interventions: Other: Laboratory Biomarker Analysis |
Completed |
Study Name: Study of RAD001 in Adenoid Cystic Carcinoma Condition: Adenoid Cystic Carcinoma Date: 2010-05-31 Interventions: Drug: RAD001 RAD001 10 mg po daily medication |
Active, not recruiting |
Study Name: Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck Condition: Carcinoma, Adenoid Cystic Head and Neck Neoplasms Date: 2010-02-08 Interventions: Drug: Nelfinavir 1250 mg Nelfinavir twice daily Monday - Sunday |
Completed |
Study Name: A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Condition: Adenoid Cystic Carcinoma Salivary Gland Cancer Date: 2009-04-20 Interventions: Drug: Sunitinib 37.5 mg taken orally, daily every 28-day cycles |